On-demand Webinar | Recorded: November 18, 2025 | Duration: 51 minutes
As biologics programs advance towards commercialization, late-stage development presents unique challenges: from scaling processes efficiently to ensuring regulatory readiness and cost competitiveness. Delays in tech transfer, lengthy process characterization, and inefficient scale-up can all negatively impact timelines, budgets, and confidence.
This webinar explores how biologics innovators can overcome these hurdles through pragmatic, efficiency-driven approaches to late-stage development.
Our experts discuss strategies for:
- Accelerating process characterization to reducing timelines while maintaining analytical depth and regulatory compliance,
- Executing seamless tech transfers tominimizing risk and ensuring smooth scale-up,
- Preparing for cost-competitive commercial manufacturing tooptimizing yields and readiness for market supply.
Access the on-demand webinar to learn how biologics can be delivered better, smarter, and faster.
Featured Speakers
Barbara Fedejko-Kap
Group Director of Analytical Development, Rezon Bio
Barbara leads the technical, strategic, and operational planning of analytical development programs at Rezon Bio. Her expertise focuses on optimizing value, time, resources, and risk across the biologics lifecycle. With a Ph.D. in Biotechnology from Gdańsk University of Technology and over a decade of experience, she combines deep scientific knowledge with advanced analytical technologies to accelerate biologics development without compromising quality.
Dawid Suwala
Drug Substance Manufacturing Director, Rezon Bio
Dawid oversees commercial GMP manufacturing and tech transfer operations across Rezon Bio’s facilities in Poland. With extensive experience in upstream and downstream processing, he has successfully managed multiple technology transfers and GMP manufacturing programs under EMA and FDA oversight. His leadership focuses on efficiency, quality, and team development.
Felix Faupel
Chief Business Officer, Rezon Bio
Felix drives Rezon Bio’s global commercial strategy and client partnerships. With a decade of experience across the biopharmaceutical and CDMO sectors, he blends scientific insight with strong business acumen. He played a key role in shaping Rezon Bio’s CDMO strategy and positioning, and is passionate about building transparent, collaborative relationships that create long-term value for clients and their patients.
